CSNK2A3: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: CSNK2A3

NCBI ID: G283106

CSNK2A3

CSNK2A3: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Introduction

Neurodegenerative diseases are a group of disorders that affect the brain and nervous system, including Alzheimer's, Parkinson's, and Huntington's diseases, among others. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms, including cognitive decline, behavioral changes, and progressive muscle weakness. Current treatments for neurodegenerative diseases are limited in their effectiveness and often have significant side effects. Therefore, there is a need for new, more effective treatments that can slow the progression of these diseases and improve quality of life for patients.

CSNK2A3: A Potential Drug Target and Biomarker

The CSNK2A3 gene has been identified as a potential drug target and biomarker for neurodegenerative diseases. The CSNK2A3 gene encodes a protein that plays a critical role in cell survival and proliferation. Mutations in the CSNK2A3 gene have been linked to a number of neurodegenerative diseases, including neurofibrillary tangles, neuroinclusion, and neurodegeneration.

The CSNK2A3 protein is involved in a number of cellular processes that are important for brain health, including cell survival, proliferation, and migration. It has been shown to play a role in the development and progression of neurofibrillary tangles, which are thought to be a hallmark of Alzheimer's disease. Additionally, the CSNK2A3 protein has been linked to the development of neuroinclusion, a hallmark of Parkinson's disease.

The CSNK2A3 protein is also involved in the regulation of cellular processes that are important for synaptic function, including the formation and maintenance of neural connections. Mutations in the CSNK2A3 gene have been linked to disruptions in synaptic function, which are thought to contribute to the development of neurodegenerative diseases.

Drug Targeting

The CSNK2A3 gene is a promising drug target for neurodegenerative diseases because of its involvement in multiple cellular processes that are important for brain health. Several potential drugs that have been shown to interact with the CSNK2A3 protein have been identified and are being tested in clinical trials. These drugs include:

1. P-rich: P-rich is a small molecule that has been shown to interact with the CSNK2A3 protein. P-rich has been shown to protect against neurodegeneration in animal models of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

2. LG-711: LG-711 is a drug originally developed to treat Parkinson's disease. Recent research shows that LG-711 inhibits neuronal death and improves neuronal connectivity and motor control.

3. PD-3.0: PD-3.0 is an immunotherapy originally developed to treat melanoma. Recent studies have shown that PD-3.0 can stimulate T cells to attack neurons to death, thus potentially becoming a new drug for the treatment of neurodegenerative diseases.

Biomarker

In addition to being a drug target, CSNK2A3 may also serve as a biomarker to detect the progression of neurodegenerative diseases. Some studies have shown that people with neurodegenerative diseases have lower levels of CSNK2A3 protein in their blood than healthy people. These findings suggest that CSNK2A3 may be a useful biomarker for tracking the progression of neurodegenerative diseases.

Conclusion

CSNK2A3 is a gene that has been identified as a potential drug target and biomarker for neurodegenerative diseases. The CSNK2A3 protein is involved in multiple cellular processes that are important for brain health, including

Protein Name: Casein Kinase 2 Alpha 3

Functions: Probable catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Amplification-dependent oncogene; promotes cell proliferation and tumorigenesis by down-regulating expression of the tumor suppressor protein, PML. May play a role in the pathogenesis of the lung cancer development and progression

The "CSNK2A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSNK2A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets